KR20110016891A - 신경정신 장애의 치료를 위한 ｎｍｄａ 수용체 길항물질 - Google Patents

신경정신 장애의 치료를 위한 ｎｍｄａ 수용체 길항물질 Download PDF

Info

Publication number
KR20110016891A
KR20110016891A KR1020107025739A KR20107025739A KR20110016891A KR 20110016891 A KR20110016891 A KR 20110016891A KR 1020107025739 A KR1020107025739 A KR 1020107025739A KR 20107025739 A KR20107025739 A KR 20107025739A KR 20110016891 A KR20110016891 A KR 20110016891A
Authority
KR
South Korea
Prior art keywords
alkyl
compound
independently
aralkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107025739A
Other languages
English (en)
Korean (ko)
Inventor
레이몬드 제이. 딩글다인
스티븐 에프. 트레이넬리스
Original Assignee
에모리 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에모리 유니버시티 filed Critical 에모리 유니버시티
Publication of KR20110016891A publication Critical patent/KR20110016891A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020107025739A 2008-05-09 2009-05-11 신경정신 장애의 치료를 위한 ｎｍｄａ 수용체 길항물질 Ceased KR20110016891A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12709808P 2008-05-09 2008-05-09
US61/127,098 2008-05-09

Publications (1)

Publication Number Publication Date
KR20110016891A true KR20110016891A (ko) 2011-02-18

Family

ID=41265475

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107025739A Ceased KR20110016891A (ko) 2008-05-09 2009-05-11 신경정신 장애의 치료를 위한 ｎｍｄａ 수용체 길항물질

Country Status (16)

Country Link
US (1) US20110160223A1 (enExample)
EP (1) EP2296658A4 (enExample)
JP (1) JP2011520815A (enExample)
KR (1) KR20110016891A (enExample)
CN (1) CN102762207A (enExample)
AU (1) AU2009244082A1 (enExample)
BR (1) BRPI0912362A2 (enExample)
CA (1) CA2722776A1 (enExample)
CO (1) CO6341558A2 (enExample)
EA (1) EA020339B1 (enExample)
IL (1) IL208895A0 (enExample)
MX (1) MX2010012186A (enExample)
NZ (1) NZ589764A (enExample)
SG (1) SG195568A1 (enExample)
WO (1) WO2009137843A2 (enExample)
ZA (1) ZA201007958B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102762554A (zh) 2010-02-16 2012-10-31 辉瑞大药厂 5-ht4受体的部分激动剂(r)-4-((4-((4-(四氢呋喃-3-基氧基)苯并[d]异*唑-3-基氧基)甲基)哌啶-1-基)甲基)四氢-2h-吡喃-4-醇
CN107936076B (zh) 2011-09-08 2021-10-15 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
WO2013169964A1 (en) * 2012-05-09 2013-11-14 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2013170072A2 (en) * 2012-05-09 2013-11-14 Neurop, Inc. Compounds for the treatment of neurological disorders
US8974365B2 (en) * 2012-11-25 2015-03-10 Steven Richard Devore Best Treatment of thalamocortical dysrhythmia
AU2014243773B2 (en) 2013-03-13 2018-12-13 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
WO2014210456A1 (en) 2013-06-28 2014-12-31 Emory University Pyrazoline dihydroquinolones, pharmaceutical compositions, and uses
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3204011A4 (en) * 2014-10-07 2018-06-20 Sage Therapeutics, Inc. Neuroactive compounds and methods of use thereof
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
CA2991214C (en) 2015-07-06 2024-04-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
JP6882996B2 (ja) 2015-07-06 2021-06-02 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法
US11117924B2 (en) 2015-07-06 2021-09-14 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3383429B1 (en) 2015-11-30 2020-10-14 INSERM - Institut National de la Santé et de la Recherche Médicale Nmdar antagonists for the treatment of tumor angiogenesis
MA44526A (fr) 2016-04-01 2021-06-02 Sage Therapeutics Inc Oxystérols et leurs méthodes d'utilisation
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MA45598B1 (fr) 2016-07-07 2021-09-30 Sage Therapeutics Inc Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA46351A (fr) 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
RU2019115113A (ru) 2016-10-18 2020-11-24 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
US11111266B2 (en) 2016-10-18 2021-09-07 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN109803656B (zh) * 2017-10-09 2021-08-31 华南农业大学 一种抗白色念珠菌的化合物及其制备方法和应用
US11981652B2 (en) 2018-03-28 2024-05-14 Emory University GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor
KR102793535B1 (ko) 2018-06-27 2025-04-11 클렉시오 바이오사이언시스 리미티드 주요 우울 장애를 치료하는 방법
JP2022504036A (ja) 2018-10-05 2022-01-13 クレキシオ バイオサイエンシーズ エルティーディー． 大うつ病性障害を治療するためのエスケタミンの投与計画
US12364672B2 (en) 2018-10-11 2025-07-22 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー． 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
EP4084786A1 (en) 2019-12-30 2022-11-09 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
CN114539129B (zh) * 2020-11-18 2023-06-09 上海中医药大学附属龙华医院 烯丙胺类双功能化合物及其用途
JP2024533182A (ja) 2021-09-02 2024-09-12 エモリー ユニバーシティー 酸性ｐＨで増強された効力を有するＮ－メチル－Ｄ－アスパラギン酸受容体のＧｌｕＮ２Ｂサブユニット選択的アンタゴニスト

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
EP0005828B1 (de) * 1978-06-06 1981-03-11 Hoechst Aktiengesellschaft Neue substituierte Phenylpiperazinderivate, diese enthaltende Arzneimittel und Verfahren zu deren Herstellung
DE2824677A1 (de) * 1978-06-06 1979-12-20 Hoechst Ag Neue substituierte phenylpiperazinderivate und verfahren zu deren herstellung
JPS55162774A (en) * 1979-06-06 1980-12-18 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS5646812A (en) * 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
JPS5649362A (en) * 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Thiocarbostyril derivative
JPS5649361A (en) * 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS579769A (en) * 1980-06-23 1982-01-19 Otsuka Pharmaceut Co Ltd 2-benzimidazolinone derivative
JPS58203968A (ja) * 1982-05-21 1983-11-28 Otsuka Pharmaceut Co Ltd イソカルボスチリル誘導体
DE3442570A1 (de) * 1984-11-22 1986-05-22 Hoechst Ag, 6230 Frankfurt Neue substituierte phenylpiperazinderivate, verfahren zu deren herstellung und die verwendung substituierter phenylpiperazinderivate als aggressionshemmer fuer tiere
JPS62252783A (ja) * 1986-02-13 1987-11-04 ワ−ナ−−ランバ−ト・コンパニ− ベンズ複素環式化合物
GB9005318D0 (en) * 1990-03-09 1990-05-02 Isis Innovation Antiarrhythmic agents
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
CA2681877A1 (en) * 1997-10-31 1999-05-14 Asubio Pharma Co., Ltd. Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same
IL145584A0 (en) * 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
WO2002028814A2 (en) * 2000-10-06 2002-04-11 Regents Of The University Of California Nmda receptor channel blocker with neuroprotective activity
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
DE10248925A1 (de) * 2002-10-15 2004-04-29 Proteosys Ag Neue Verbindungen mit dopaminerger und/oder serotoninerger Aktivität
WO2004100956A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Method for enhancing cognition using ziprasidone
MXPA05012493A (es) * 2003-05-27 2006-05-25 Forest Laboratories Combinacion de un antagonista del receptor de nmda y un inhibidor selectivo de reabsorcion de serotonina para el tratamiento de depresion y otros trastornos de estado de animo.
HUP0401526A2 (en) * 2004-07-29 2006-04-28 Richter Gedeon Vegyeszet Aryloxy acetic acid amide derivatives, pharmaceutical compositions comprising thereof, methods for their preparation and their use
AU2005277055B2 (en) * 2004-08-23 2011-03-31 Emory University Improved selection of-pH dependent compounds for in vivo therapy
JP2009500440A (ja) * 2005-07-12 2009-01-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 性欲障害治療用医薬組成物
TWI329641B (en) * 2005-08-31 2010-09-01 Otsuka Pharma Co Ltd (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same
US7935706B2 (en) * 2006-02-23 2011-05-03 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
WO2008020306A2 (en) * 2006-08-18 2008-02-21 Pfizer Products Inc. Isoindole derivatives
CN101815518B (zh) * 2007-06-29 2013-01-09 埃莫里大学 用于神经保护的nmda受体拮抗剂

Also Published As

Publication number Publication date
US20110160223A1 (en) 2011-06-30
CN102762207A (zh) 2012-10-31
MX2010012186A (es) 2011-02-22
EP2296658A4 (en) 2014-01-15
WO2009137843A9 (en) 2010-03-11
CO6341558A2 (es) 2011-11-21
WO2009137843A2 (en) 2009-11-12
EA020339B1 (ru) 2014-10-30
BRPI0912362A2 (pt) 2015-10-06
EA201071291A3 (ru) 2014-02-28
IL208895A0 (en) 2011-01-31
JP2011520815A (ja) 2011-07-21
CA2722776A1 (en) 2009-11-12
ZA201007958B (en) 2011-07-27
SG195568A1 (en) 2013-12-30
AU2009244082A1 (en) 2009-11-12
EP2296658A2 (en) 2011-03-23
EA201071291A2 (ru) 2011-04-29
NZ589764A (en) 2012-10-26

Similar Documents

Publication Publication Date Title
KR20110016891A (ko) 신경정신 장애의 치료를 위한 ｎｍｄａ 수용체 길항물질
EP2170334B1 (en) Nmda receptor antagonists for neuroprotection
BR112020014189A2 (pt) pró-fármacos de quetamina, composições e usos destas
CN105130957A (zh) 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
EP2776387B1 (en) Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction
JP6046149B2 (ja) Ｈ３受容体阻害剤としてのピペリジン及びピペラジン環を含むカルバメート／尿素誘導体
US20140148432A1 (en) Compounds for the Treatment of Neurological Disorders
TW202440561A (zh) 四氫噻吩衍生物及其在醫藥上的應用
RS55916B1 (sr) Derivati aminociklobutana, metod za dobijanje istih i njihova upotreba kao lekova
JP7522203B2 (ja) Ｋｖ３モジュレーター
EP3867244B1 (en) 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
JP2003192660A (ja) 尿素誘導体
KR20200097301A (ko) 이미다조피리딘 유도체 및 이의 약제로서의 용도
JP2007186434A (ja) 医薬組成物
AU2013203941A1 (en) NMDA receptor antagonists for the treatment of neuropsychiatric disorders
US20140275060A1 (en) Compounds for the treatment of neurologic disorders
HK40059626B (en) 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
HK40059626A (en) 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
AU2013203908A1 (en) Compounds for the treatment of neurologic disorders
HK1146902B (en) Nmda receptor antagonists for neuroprotection
HK1240927B (zh) 氨基环丁烷衍生物、其制备方法及其用作药物的用途
HK1212968B (en) Aminocyclobutane derivatives, method for preparing same and the use thereof as drugs

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20101116

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140127

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150720

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20151022

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150720

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I